Silvio Traversa
Chief Tech/Sci/R&D Officer bij SIENNA BIOPHARMACEUTICALS, INC.
Profiel
Silvio Traversa is currently the Chief Scientific Officer at Sienna Biopharmaceuticals, Inc. He was previously the Chief Scientific Officer at Creabilis Therapeutics Srl from 2007 to 2016.
Prior to that, he worked as a Principal at.
Industria Farmaceutica Serono SpA.
Traversa received his undergraduate and doctorate degrees from the University of Turin and his graduate degree from Harvard Business School.
Actieve functies van Silvio Traversa
| Bedrijven | Functie | Begin |
|---|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-12-2016 |
Eerdere bekende functies van Silvio Traversa
| Bedrijven | Functie | Einde |
|---|---|---|
Creabilis Therapeutics Srl
 Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Chief Tech/Sci/R&D Officer | 01-12-2016 |
| Industria Farmaceutica Serono SpA | Corporate Officer/Principal | - |
Opleiding van Silvio Traversa
| University of Turin | Doctorate Degree |
| Harvard Business School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Industria Farmaceutica Serono SpA | |
Creabilis Therapeutics Srl
Creabilis Therapeutics Srl Pharmaceuticals: MajorHealth Technology Creabilis Therapeutics SRL discovers, develops, and markets prescription medicines to treat skin disease. Its products include CT200 and CT335, which is used to treat Behcet's disease; and CT327, which is used for the treatment of psoriasis, atopic dermatitis, and overgrowth of keratinocytes. The company’s products also include CT400, which is used for developing inhibitors of HGMB-1; and CT500 for the treatment of inflammatory disorders. The company was founded by Alfredo Boni in 2003 and is headquartered in Colleretto Giacosa, Italy. | Health Technology |
